Open AccessTreatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients
Author(s) -
Eukene Rojo,
M J Casanova,
Javier P. Gisbert
Publication year - 2019
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2019.6655/2019
Subject(s) - medicine , budesonide , microscopic colitis , refractory (planetary science) , colitis , gastroenterology , intensive care medicine , corticosteroid , disease , inflammatory bowel disease , metallurgy , materials science
Microscopic colitis is a common cause of chronic watery diarrhea with a great impact on patient quality of life. Microscopic colitis includes two histological subtypes: collagenous colitis and lymphocytic colitis. Due to the increasing incidence and awareness of this disease over the last decades, several international guidelines have been recently published. However, there is still significant heterogeneity in the management of these patients, and treatments without solid scientific evidence support are often used in clinical practice. This article reviews the therapeutic role of budesonide in microscopic colitis and summarizes the current evidence regarding other treatments available for this disease, especially for the management of refractory patients. Finally, an updated treatment algorithm is proposed.